SCHEMBL7123876

SCHEMBL7123876

O=[N+]([O-])c1ccccc1Oc1ccc(I)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
HPGD P15428 1/20 0.56
LTA4H P09960 2/20 0.53
PTGS1 P23219 1/20 0.53
PTGS2 P35354 1/20 0.53
ALDH1A1 P00352 5/20 0.53
TDP1 Q9NUW8 2/20 0.53
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
RECQL P46063 1/20 0.51
HSPB1 P04792 1/20 0.49
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTT P42858 2/20 0.47
ESR2 Q92731 1/20 0.46
MEN1 O00255 3/20 0.45
MAPT P10636 1/20 0.45
TTR P02766 1/20 0.44
ALB P02768 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238962 0.85 L3MBTL1 (0.62) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL1283885 0.84 HSPB1 (0.67) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL6750951 0.84 L3MBTL1 (0.57) L3MBTL1HPGDLTA4HPTGS1PTGS2
2,4'-Oxybis(Nitrobenzene) SCHEMBL9474586 0.84 HSPB1 (0.62) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL7021137 0.83 L3MBTL1 (0.56) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL641831 0.83 HPGD (0.65) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL8695351 0.83 L3MBTL1 (0.60) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL2649297 0.83 L3MBTL1 (0.70) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL10944795 0.83 L3MBTL1 (0.56) L3MBTL1HPGDLTA4HPTGS1PTGS2
SCHEMBL29901085 0.83 L3MBTL1 (0.70) L3MBTL1HPGDLTA4HPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM L3MBTL1 2231/4885HPGD 919/4885LTA4H 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.